News - MSTrials - MS Research Australia


13 November, 2019

The first ever treatment for secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, has been approved in Australia.

15 October, 2019

Although there has been quite a bit of research into the contribution of genes to the risk of […]

14 October, 2019

Myelin oligodendrocyte glycoprotein (MOG) antibody is associated with many demyelinating conditions, but it has not be characterised in-depth. […]

21 September, 2019

Australian researchers funded by MS Research Australia have potentially found new neurodegenerative biomarkers for MS progression.

21 September, 2019

A large international study led by an Australian researcher has identified risk factors that may contribute to conversion to secondary progressive MS.

04 September, 2019

Secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, currently has no […]

26 August, 2019

The PBAC has recommended the PBS criteria for two existing MS medications, Gilenya and Tysabri, be broadened which would allow reimbursement for young people with MS.

20 August, 2019

Australian researchers used cognitive eye movement tasks and MRI to look at changes in cognition and brain activity in people with CIS

20 August, 2019

Up to 65% of people with MS report difficulties with thinking and memory, but many cognitive tests cause […]

20 August, 2019

Previous research suggests that opicinumab treatment might enhance remyelination. Results from a phase 2 clinical trial testing the […]

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search